T48. ANTIPSYCHOTIC EFFICACY OF EVENAMIDE (NW-3509) IS DUE TO MODULATION OF GLUTAMATERGIC DYSREGULATION

Ravi Anand1, Emma C. Forrest2, Richard D. Hartman3, Stephen M Graham2, Laura Faravelli2
1Anand Pharma Consulting; 2Newron Pharmaceuticals; 3NeurWrite LLC

Background: Over 70% of schizophrenic patients discontinue treatment with first (F)- or second-generation antipsychotics (SGA) due to dissatisfaction with their therapeutic effects; median time to discontinuation ranges from 3–7 months (1). Switching to another antipsychotic, except clozapine, did not yield better results (2). These results indicate it is essential to modulate mechanisms other than dopaminergic (DA)/serotonergic (5-HT) systems to improve symptoms of schizophrenia (SCZ). Increasingly, NMDA receptor (NMDAR) hypofunction (3) and hippocampal hyperactivity (4) are implicated in the dysregulation of mesolimbic DA and glutamate (Glu) neurons, leading to increasing synaptic activity of Glu in the PFC (5). Augmenting the effects of current antipsychotics with Glu release inhibitors may improve symptoms of psychosis in patients with SCZ.

Evenamide does not interact with monoaminergic (DA, 5-HT, NA, H) pathways affected by current antipsychotics, or with >130 different targets involved in CNS activity, except for sodium channels, leading to modulation of Glu release. Evenamide shows efficacy in animal models of SCZ as monotherapy and as an add-on to FGA or SGA, irrespective of whether impairment was spontaneous, or induced by amphetamine, NMDAR antagonists or stress.

Methods: In a pilot, proof of mechanism, randomized, double-blind, placebo-controlled, parallel group, 4-week trial, evenamide (n=50; 15–25 mg bid) or placebo (n=39) was added to patients with SCZ worsening on their current antipsychotic dosages of risperidone (RIS; ≥2 mg/day) or aripiprazole (ARI; ≥10 mg/day), in 2 sites in the US (n=61) and 3 in India (n=28).

Results: 89 patients with SCZ (mean baseline PANSS total: 62.9 ± 7.4; CGI-S: 3.5 ± 0.5), experiencing break-through psychotic symptoms on previously effective and stable doses of RIS (mean dose: 4.2 ± 2.0 mg/day; n=70) or ARI (mean dose: 19.7 ± 7.0 mg/day; n=19) were randomized (1:3:1 ratio) to treatment with evenamide or placebo. Analyses demonstrated the addition of evenamide to RIS or ARI was associated with statistically significant efficacy, based on the PANSS Positive Symptoms sub-scale (mean change, responders), and CGI-C responder rates. The study treatments were very well tolerated; 2 patients on evenamide discontinued treatment due to AEs (atrial fibrillation and seizure). The most common AEs (evenamide vs placebo [%]), were somnolence (16 vs 12.8%), insomnia (10 vs 6%) and headache (6 vs 0%).

Discussion: Addition of evenamide in patients worsening on SGA modulating DA/5-HT significantly improved positive symptoms and CGI. No AEs such as EPS, endocrine, or sexual side effects, or weight gain were noted. These data indicate that evenamide’s Glu antagonism, demonstrated in preclinical experiments, is of value in patients worsening on current antipsychotics. Evenamide, as monotherapy or add-on, has reversed ketamine- and PCP-induced worsening of PPI. The results in the pilot clinical trial demonstrated an absence of side effects common with DA/5-HT blockers, and a rapid onset of action mediated by evenamide targeting altered Glu transmission in patients in whom SGA treatment had lost its efficacy. Efficacy of evenamide as add-on to antipsychotics would revolutionize development of novel antipsychotics targeting aberrant firing and Glu transmission in SCZ. Potentially pivotal studies with evenamide are in planning to demonstrate that the addition of evenamide, a Glu release inhibitor, augments antipsychotic efficacy in patients worsening on current antipsychotics, and in patients with treatment-resistant SCZ not responding/worsening on clozapine.

T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION

Monika Schlögelhofer1, Patrick D. McGorry2, Barnaby Nelson3, Connie Markulev2, Hok Pan Yuen2, Miriam Schäfer2, Nilufar Mosaheb1, Stefan Smesny4, Ian B. Hickie1, Gregor Berger1, Eric Y. H. Chen1, Lieuwe de Haan1, Dorien H. Nieman5, Merete Nordentoft6, Anita Riecher-Rössler7, Swapna Verma8, Andrew Thompson2, Alison Ruth Yung2, G. Paul Amminger1
1Medical University of Vienna; 2Orygen, the National Centre of Excellence in Youth Mental Health; 3Orygen, the National Centre of Excellence in Youth Mental Health, Medical University of Vienna; 4University Hospital Jena; 5University of Sydney; 6Child and Adolescent Psychiatric Service of the Canton of Zürich; 7University of Hong Kong; 8Academic Medical Center; 9Psychiatric Centre Bispebjerg; 10Psychiatric University Clinics Basel; 11Institute of Mental Health; 12University of Manchester, Greater Manchester Mental Health NHS Foundation Trust; 13Orygen, the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Medical University of Vienna

Background: Adherence to a medication is generally defined as the extent to which patients take medications as prescribed by their health care providers. Poor adherence to study medication is not uncommon posing a major challenge to treatment trials. However, poor adherence may not be randomly distributed but rather be associated with demographic or illness factors. The aim of the present study was to identify factors associated with adherence to study medication in young people at ultrahigh risk of psychosis who participated in the NEURAPRO study.

Methods: Secondary analysis of data collected in a multi-centre, double-blind, placebo-controlled, randomized clinical trial to prevent or delay the onset of psychosis in participants at ultrahigh risk of psychosis testing omega-3 polyunsaturated fatty acids (omega-3 PUFAs) vs. placebo, in combination with cognitive behavioural case management (NEURAPRO) were included in this analysis. Measures included the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS), the Montgomery Asberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), the Social and Occupational Functioning Assessment Scale (SOFAS), and the Global Functioning; Social and Role scales. Adherence to the study medication was assessed monthly for each participant based on capsule count. The mean adherence rating over the 6-month intervention period was then computed and categorized as either adherent (>25% of capsules returned) or non-adherent (>25% of capsules returned). Transition to psychosis was defined on the basis of operationalized criteria and assessed with the Comprehensive Assessment of the At-Risk Mental State. Levels of omega-3 PUFAs in fish oil, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (amongst other fatty acids) were measured as percentage of total fatty acids in erythrocytes at baseline and at month 6 (end-of-intervention).

Results: Of 304 randomised participants, 57.9% (N = 176) were non-adherent (>25% of capsules returned) and 128 (42.1%) were adherent (>25% of capsules returned) to the study medication. No sex differences were observed for adherence rates. At baseline the omega-3 index (EPA+DHA) was significantly lower in the non-adherent group (P = 0.018). The non-adherent group had significant lower scores on the SOFAS (P = 0.001) and the Global Functioning: Social and Role Scale at baseline assessment (P < 0.001 and P = 0.020, respectively) compared to the adherent group. No statistically significant differences were observed on symptom measures at baseline (BPRS, SANS, MADRS, YMRS). The cumulative transition to psychosis rate at month 12 was significantly higher in the non-adherent group compared to the adherent group (14.8% vs. 4.7%: Log rank test: P < 0.001).
T50. SYMPTOMATIC AND FUNCTIONAL RESPONSE TO BREXPIPAZOLE TREATMENT IN PATIENTS WITH ACUTE SCHIZOPHRENIA BY AGE

Catherine Weiss*1, Erin MacKenzie2, Francois Therrien1, Peter Zhang1, Stine Meehan3
1Otsuka Pharmaceutical Development & Commercialization, Inc; 2Lundbeck Canada, Inc; 3H. Lundbeck A/S

Background: Atypical antipsychotics are the mainstay of treatment for schizophrenia, and have a meaningful effect on positive symptoms and agitation/aggression. More recently, treatment goals have shifted to target functioning: a cycle of deterioration often occurs in early schizophrenia in which recurring relapse results in decreased functioning.

Brexiprazole is a serotonin-dopamine activity modulator that is a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors, all at subnanomolar potency. The efficacy of brexiprazole has been shown in both short- and long-term studies. In this post-hoc analysis from three short-term studies, the proportion of patients achieving symptomatic and functional response was assessed, grouped by age at baseline.

Methods: Efficacy and functioning data were pooled from three 6-week, double-blind, placebo-controlled studies in hospitalized patients with acute exacerbation of schizophrenia (Vector [NCT01396421]; Beacon [NCT01396613]; and Lighthouse [NCT01810380]), and stratified according to age at baseline (18–35 years; and 36–65 years). For the current analyses, response was defined as reduction in PANSS score of ≥30% from baseline; a CGI-I score of 1 or 2 (much improved or functioning); a cycle of deterioration often occurs in early schizophrenia in which recurring relapse results in decreased functioning.

T51. TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA WITH TRANSCRANIAL CURRENT STIMULATION (tDCS): RESULTS OF RANDOMIZED, DOUBLE-BLINDED, SHAM-CONTROLLED TRIAL

Leandro Valiengo*1, Pedro Gordon1, Mauricio Serpa1, Acioly Lacerda2, Wagner Gattaz1, Martinus Van de Bilt1, Helio Helkis1, Andre Brunoni1
1University of Sao Paulo; 2Centro de Pesquisa e Ensaios Clinicos Sinapse-Bairral

Background: The negative symptoms of schizophrenia cause significant distress and impairment. The treatment of them is a challenge, with medications having none or little effect. So, new treatments are necessary for this condition. The aim of the study was to ascertain the efficacy of tDCS in treating negative symptoms of schizophrenia.

Methods: This study was designed to be a randomized, sham-controlled, double-blinded trial using tDCS for the treatment of negative symptoms of schizophrenia. One-hundred (here we analyzed only 70% of the sample, the remaining will be presented at the meeting) patients will be enrolled and submitted to ten tDCS session over the left dorsolateral prefrontal cortex (anodal stimulation) and left temporo-parietal junction-left (cathodal stimulation), over 5 consecutive days, with 2 mA of current. Participants were assessed with clinical and neuropsychological tests before and after the intervention. The primary outcome was change (over time and across groups) in the scores of the Negative Subscale of Positive and Negative Symptoms Syndrome (PANSS). Our secondary outcomes consist of others scales as SANS (Scale of Assessment of Negative Symptoms), and the AHRs (Auditory Hallucinations Rating Scale).

Results: From 70% of the sample the active tDCS was significantly superior to sham at endpoint at 6 weeks by negative sub scale of PANSS (mean difference, 3.5 points; SD=6.2; P<.05). The total PANSS and the hallucinations scale had no differences between both groups. The other times of analysis were not found differences between sham and active groups. The others scales (Calgary and SANS) have not been evaluated yet.

Discussion: The results of our studies suggests a potential role of tDCS for the treatment of negative symptoms of schizophrenia. The effect size was small. This is the biggest study with tDCS for treating negative symptoms of schizophrenia until now. At the meeting all the data will be analyzed (100 patients), it these could change our preliminary results.

T52. N-ACETYL-CYSTEINE ADD-ON TREATMENT LEADS TO AN IMPROVEMENT OF FORNIX WHITE MATTER INTEGRITY IN EARLY PSYCHOsis

Paul Klauser1, Lijing Xin1, Margot Fournier1, Alessandra Griffa1, Martine Cleusix1, Raoul Jenni1, Michel Cuenod1, Rolf Gruetter1, Patric Hagmann1, Philippe Conus1, Philipp Baumann*2, Kim Q. Do1
1Lausanne University Hospital; 2DP-CHUV (TIPP)

Background: Beneficial effects of N-acetylcysteine (NAC) on negative symptoms in chronic schizophrenia have been reported in two studies. A recent study in early psychosis from our group, did not report significant improvement in negative symptoms (potentially linked to the modest baseline levels) but showed improvement in cognition (i.e. processing speed) and an increase in the brain antioxidant glutathione (GSH) levels, indicating good target engagement. Indeed, research in animal models highlights the critical role of redox regulation by brain GSH for white matter maturation and maintenance. Given the strong evidence of white matter (WM) alterations in schizophrenia...